Prudence Ive to Antitubercular Agents
This is a "connection" page, showing publications Prudence Ive has written about Antitubercular Agents.
Connection Strength
0,629
-
Treatment outcomes among patients admitted to hospital with antiretroviral and/or antituberculosis drug-induced liver injury. S Afr Med J. 2021 Apr 30; 111(5):474-481.
Score: 0,155
-
Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells. PLoS One. 2016; 11(7):e0158262.
Score: 0,111
-
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015 May 02; 385(9979):1738-1747.
Score: 0,101
-
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93.
Score: 0,089
-
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20; 365(16):1482-91.
Score: 0,080
-
Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011; 16(4):527-34.
Score: 0,076
-
Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009 Mar 27; 23(6):707-15.
Score: 0,017